Synonym
PNR-4-20; PNR4-20; PNR 4-20; PNR-420; PNR-4 20; PNR420; PNR 4 20;
IUPAC/Chemical Name
(Z)-2-((1-(4-fluorobenzyl)-1H-indol-3-yl)methylene)quinuclidin-3-one
InChi Key
YLLPMBLABONSAM-XKZIYDEJSA-N
InChi Code
InChI=1S/C23H21FN2O/c24-19-7-5-16(6-8-19)14-26-15-18(20-3-1-2-4-21(20)26)13-22-23(27)17-9-11-25(22)12-10-17/h1-8,13,15,17H,9-12,14H2/b22-13-
SMILES Code
O=C1/C(N2CCC1CC2)=C/C3=CN(CC4=CC=C(F)C=C4)C5=C3C=CC=C5
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
Soluble in DMSO
Shelf Life
>3 years if stored properly
Drug Formulation
This drug may be formulated in DMSO
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.9001
Preparing Stock Solutions
The following data is based on the
product
molecular weight
360.43
Batch specific molecular weights may vary
from batch to batch
due to the degree of hydration, which will
affect the solvent
volumes required to prepare stock solutions.
| Concentration / Solvent Volume / Mass |
1 mg |
5 mg |
10 mg |
| 1 mM |
1.15 mL |
5.76 mL |
11.51 mL |
| 5 mM |
0.23 mL |
1.15 mL |
2.3 mL |
| 10 mM |
0.12 mL |
0.58 mL |
1.15 mL |
| 50 mM |
0.02 mL |
0.12 mL |
0.23 mL |
1: Ford BM, Cabanlong CV, Tai S, Franks LN, Penthala NR, Crooks PA, Prather PL, Fantegrossi WE. Reduced Tolerance and Asymmetrical Crosstolerance to Effects of the Indole Quinuclidinone Analog PNR-4-20, a G Protein-Biased Cannabinoid 1 Receptor Agonist in Mice: Comparisons with Δ9-Tetrahydrocannabinol and JWH-018. J Pharmacol Exp Ther. 2019 May;369(2):259-269. doi: 10.1124/jpet.118.252965. Epub 2019 Mar 4. PMID: 30833484; PMCID: PMC6447997.
2: Ford BM, Franks LN, Tai S, Fantegrossi WE, Stahl EL, Berquist MD, Cabanlong CV, Wilson CD, Penthala NR, Crooks PA, Prather PL. Characterization of structurally novel G protein biased CB1 agonists: Implications for drug development. Pharmacol Res. 2017 Nov;125(Pt B):161-177. doi: 10.1016/j.phrs.2017.08.008. Epub 2017 Aug 23. PMID: 28838808; PMCID: PMC5849406.
